These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33612166)

  • 1. Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
    Vahdani K; Thaung C; Rose GE
    Ophthalmology; 2021 Mar; 128(3):402. PubMed ID: 33612166
    [No Abstract]   [Full Text] [Related]  

  • 2. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
    Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
    Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
    [No Abstract]   [Full Text] [Related]  

  • 3. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Gentile M; Shanafelt TD; Reda G; Mauro FR; Zirlik K; Ciolli S; Laurenti L; Del Principe MI; Rossi D; Di Renzo N; Molica S; Angrilli F; Coscia M; Chiarenza A; Giordano A; Cutrona G; Chaffee KG; Parikh SA; Uccello G; Innocenti I; Tripepi G; D'Arrigo G; Vigna E; Recchia AG; Herishanu Y; Shvidel L; Tadmor T; Cortelezzi A; Del Poeta G; Gaidano G; Di Raimondo F; Neri A; Ferrarini M; Foà R; Polliack A; Morabito F
    Leukemia; 2018 Aug; 32(8):1869-1873. PubMed ID: 29588545
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab/Bendamustine treatment of chronic lymphatic leukemia leads to sustained remission of antiphospholipid antibodies.
    Ames PR; Merashli M; Gentile F
    Eur J Immunol; 2019 Jun; 49(6):969-970. PubMed ID: 30893471
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Mulay S; Boruchov A
    Leuk Lymphoma; 2015 Mar; 56(3):805-7. PubMed ID: 24913498
    [No Abstract]   [Full Text] [Related]  

  • 7. Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience.
    Laurenti L; Autore F; Innocenti I; D'Arena G; Coscia M; Mondello P; Chiusolo P; Bellesi S; Efremov DG; Sica S; Mauro FR
    Leuk Lymphoma; 2016 Oct; 57(10):2429-31. PubMed ID: 26818825
    [No Abstract]   [Full Text] [Related]  

  • 8. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
    Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
    Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Soumerai JD; Davids MS; Werner L; Fisher DC; Armand P; Amrein PC; Neuberg D; Hochberg EP; Brown JR; Abramson JS
    Leuk Lymphoma; 2019 Dec; 60(12):2931-2938. PubMed ID: 31074316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.
    Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V
    Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.
    Fürstenau M; Hopfinger G; Robrecht S; Fink AM; Al-Sawaf O; Langerbeins P; Cramer P; Tresckow JV; Maurer C; Kutsch N; Hoechstetter M; Dreyling M; Lange E; Kneba M; Stilgenbauer S; Döhner H; Hensel M; Kiehl MG; Jaeger U; Wendtner CM; Goede V; Fischer K; von Bergwelt-Baildon M; Eichhorst B; Hallek M; Theurich S
    Leukemia; 2020 Apr; 34(4):1177-1181. PubMed ID: 31728057
    [No Abstract]   [Full Text] [Related]  

  • 13. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
    Zoellner AK; Höhler T; Fries S; Böhme A; Kiewe P; Kellermann L; Dreyling M
    Ann Hematol; 2016 May; 95(6):853-61. PubMed ID: 27021305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
    Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
    Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
    Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
    Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended follow-up of CD4
    Gaiolla R; Hartley S; Beech A; Knight H; Smith D; Bishton M; Fox CP; Martinez-Calle N
    Hematol Oncol; 2021 Feb; 39(1):137-140. PubMed ID: 32860715
    [No Abstract]   [Full Text] [Related]  

  • 18. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Direct Antiglobulin Test Negativity after Bendamustine and Rituximab Treatment in Chronic Lymphocytic Leukemia: Two Cases.
    Eren R; Suyanı E
    Turk J Haematol; 2018 Nov; 35(4):312-313. PubMed ID: 29983407
    [No Abstract]   [Full Text] [Related]  

  • 20. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
    Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
    Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.